SWOG clinical trial number
SWOG-9521

Evaluation of Nuclear p53 in Patients with Epithelial Ovarian Cancer Patients Registered to SWOG-8835, Ancillary

Closed
Phase
Published
Abbreviated Title
Evaluation of Nuclear p53 in Patients with Epithelial Ovarian Cancer Patients Registered to SWOG-8835, Ancillary
Activated
03/01/1996
Closed
11/01/1998
Participants
NCORP, Members, Medical Oncologists

Research committees

Gynecologic Cancer

Publication Information Expand/Collapse

2002

Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy, and its prognostic role: a Southwest Oncology Group ancillary study

D Hawes;PY Liu;FM Muggia;S Wilczynski;R Cote;J Felix;K Terada;RJ Belt;DS Alberts Gynecologic Oncology 87:17-23

1999

Concordance of pre-and post- chemotherapy p53 immunostaining, and its prognostic significance in epithelial ovarian cancer (EOC) receiving intraperitoneal (IP) consolidation: A Southwest Oncology Group study (SWOG-9521).

L Pandit;PY Liu;FM Muggia;JC Felix;D Hawes;KY Terada;JC Paradelo;RJ Cote;DS Alberts Proc of the American Society of Clinical Oncology 18:382a(#1475)